Abstract Details

Title Microglial Microvesicles: Useful Prognostic Tool for Mild Cognitive Impairment and Alzheimer Disease Patients

Topic Aging and Dementia

Presentation(s) P03 - (-)

Poster/Presentation
Number 079

Objective

Background BACKGROUND: Microglial microvesicles have been indicated as important mediators of intercellular communication and are emerging as new biomarkers of neuroinflammation and neurodegeneration. Many studies using PET techniques on Alzheimer disease have recently demonstrated the role of microglia in identifying MCI converters from Healthy Controls and monitoring AD progression. Our previous study on AD patients already showed an increase of MMVS levels in comparison to MCI and Healthy controls.

Design/Methods DESIGN/METHODS: 60 patients affected by MCI and 110 affected by AD were recruited at San Raffaele Hospital and evaluated every 6 months in a 3years-study.Patients underwent at diagnosis CSF, MRI and neuropsychological assessment analysis. 200 uL of CSF were analyzed by flow cytometry (Annexin V, IB4) to detect Microglial Microvesicles while 200 ul of CSF were used to test cytokines (IL1b, IL6, CCL2, TNFalfa, CCL17, CCL22, YKL-40) by gene expression assays.

Results RESULTS: Patients with a rapidly progressive form of AD show higher MMVs level, with a correlation with M1 cytokines and and inverse correlation with CSF Beta-amiloid. Also MCI patients that converted to AD show higher MMVs level, but no correlation with the cytokine profile or with other CSF markers was evident. Neuroradiological analysis (DTI, fMRI) are ongoing.

Conclusions CONCLUSIONS: Microglial microvesicles may be used as markers for monitoring neuroinflammation in dementia patients. Our finding suggest that microglial activation occurs even in the earlier stages of the disease and may be an useful tool for stratifying patients at increased risk of rapid progression of disease.

Authors/Disclosures
Dacia Dalla Libera, MD (San Raffaele Hospital) PRESENTER	No disclosure on file
Federica Agosta (San Raffaele Scientific Institute)	Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
	No disclosure on file
Stephen Krieger, MD, FAAN (Mount Sinai Dept of Neurology)	Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Krieger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Krieger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cycle. The institution of Dr. Krieger has received research support from Novartis. The institution of Dr. Krieger has received research support from Bristol Myers Squibb. The institution of Dr. Krieger has received research support from Biogen. The institution of Dr. Krieger has received research support from Sanofi.
	No disclosure on file
Giuseppe Magnani	Giuseppe Magnani has nothing to disclose.
	No disclosure on file
	No disclosure on file
Giancarlo Comi, MD (University Vita-Salute)	Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aspen Healthcare. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Rewind.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Roberto Furlan	Roberto Furlan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Roberto Furlan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Roberto Furlan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Roberto Furlan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Roberto Furlan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Roberto Furlan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS.

��ɫ��

��ɫ��